NCT01032070

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: OSI Pharmaceuticals · Industry
• Sex: All
• Age: 1 Year – 21 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma.

Detailed description

This is a phase 2 study involving a 1:1 randomization of 40 patients with recurrent or refractory pediatric ependymoma who will receive either erlotinib or oral etoposide.

Conditions

• Recurrent or Refractory Pediatric Ependymoma

Interventions

Type	Name	Description
DRUG	erlotinib	oral
DRUG	etoposide	oral

Timeline

• Start date: 2010-09-27
• Primary completion: 2012-11-26
• Completion: 2012-11-26
• First posted: 2009-12-15
• Last updated: 2024-12-12
• Results posted: 2014-01-08

Locations

28 sites across 3 countries: United States, Canada, United Kingdom